Herpes Simplex Virus (HSV) is a double-stranded DNA virus in the Herpesviridae family. The most prevalent humans Human Type 1 (HSV-1). It can reach brain without causing symptoms [1]. Currently, antiviral drug used Acyclovir (ACV); nucleotide analogues target polymerase inhibiting viral replication. However, ACV drug-resistant occurs, especially immunocompromised patients [2]. Therefore, altern...

A quantitative real-time PCR (TaqMan) assay was developed for determination of antiviral drug susceptibility of herpes simplex virus (HSV). After short-time culture of the virus, the antiviral drug susceptibility of HSV isolates for acyclovir (ACV) was determined by measuring the reduction of the HSV type 1 (HSV-1) DNA levels in culture supernatants using real-time PCR. The 50% inhibitory conce...

treated with nucleoside analogs such as acyclovir (ACV). However, viruses can become resistant in immunosuppressed patients and in patients with acquired immunodeficiency syndrome. Because such ACV-resistant viruses are also resistant to other nucleoside analogs, new therapeutic agents with a different mode of anti-HSV action are required. Many natural products can inhibit viruses. Natural mari...

Complexes of zinc with picolinic and aspartic acids inhibit key steps of HSV-1 replication affecting different virus-specific targets. As was recently demonstrated by us, the pavine alkaloid (-)-thalimonine irreversibly inhibits HSV-1 infection in cultured cells. The aim of the present study was the evaluation of the combined effect of zinc complexes and (-)-thalimonine on uninfected and HSV-1 ...

Aciclovir (ACV) and its prodrug valacyclovir (VACV) are used to treat infections caused by herpes simplex virus (HSV) and varicella zoster virus (VZV), and as prophylaxis against cytomegalovirus (CMV) infections in immunocompromised patients. Treatment with ACV has decreased the mortality in herpes simplex encephalitis (HSE) from about 70 % to less than 30 %, and has also reduced the morbidity....

The most common therapies against human herpes virus (HSV-1) and human immunodeficiency virus (HIV-1) infectivity are based on the administration of nucleoside analogues. Acyclovir (ACV) is the drug of choice against HSV-1 infection, while the acyclic nucleoside phosphonate analogue PMPA has shown marked anti-HIV activity in a phase I and II clinical studies. As monocyte-derived macrophages are...

Herpes simplex virus (HSV), a common latent virus in humans, causes certain severe diseases. Extensive use of acyclovir (ACV) results in the development of drug-resistant HSV strains, hence, there is an urgent need to develop new drugs to treat HSV infection. Houttuynia cordata (H. cordata), a natural herbal medicine, has been reported to exhibit anti-HSV effects which is partly NF-κB-dependent...

Herpes Simplex Virus types 1 and 2 (HHV-1 and HHV-2) are human neurotropic viruses that infect most commonly the oral and genital area, respectively. Resistant viral isolates can be observed especially in immunocompromised patients. This scenario has triggered the search for new antiherpetic agents, especially those with mechanisms of action different to nucleoside analogs. The antiviral activi...

CYTOMEGALOVIRUS (CMV) remains a common complication after renal transplantation. As previously reported. CMV has a significant impact not only on the clinical outcome after transplantation but also on its cost; for patients with CMV. cost is increased 2.9-fold as a result of extended hospitalization. I The risk of developing CMV disease after renal transplantation is highest in seronegative pat...